Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Charles Wykoff
Pennsylvania State Univ Hershey Med Ctr, Department: Ophthalmology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Bayer
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Bayer is collaborating with Regeneron on the global development of study drug aflibercept under trade name Eylea.
SCORE2 Comparative Trial (SCT)
Recent trials demonstrated the efficacy of aflibercept as a treatment for macular edema due to CRVO. If bevacizumab is demonstrated to be a non-inferior treatment, this would have important economic and public health implications as bevacizumab is about 40 times cheaper than aflibercept. The trial will also investigate whether the frequency of medication injections into the eye can be reduced in eyes that responded well to treatment, and the impact of alternative treatments in eves that did not respond well to initial treatment.
Filed on December 11, 2018.
Tell us what you know about Charles Wykoff's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Charles Wykoff”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Charles Wykoff | Pennsylvania State Univ Hershey Med Ctr | Conflict of Interest | Regeneron Pharmaceuticals | $10,000 - $19,999 |
| Charles Wykoff | Pennsylvania State Univ Hershey Med Ctr | Conflict of Interest | Allergan, Inc. | $5,000 - $9,999 |
| Charles Wykoff | Jaeb Center for Health Research, Inc. | Conflict of Interest | Regeneron | $80,000 - $99,999 |
| Charles Wykoff | Pennsylvania State Univ Hershey Med Ctr | Conflict of Interest | Bayer | $0 - $4,999 |
| Charles Wykoff | Pennsylvania State Univ Hershey Med Ctr | Conflict of Interest | Genentech | $10,000 - $19,999 |
| Charles Wykoff | Jaeb Center for Health Research, Inc. | Conflict of Interest | Regeneron | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.